Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review

作者全名："Guo, Haiyang; Zhang, Jun; Qin, Chao; Yan, Hang; Luo, Xinyue; Zhou, Haining"

作者地址："[Guo, Haiyang; Zhou, Haining] Chengdu Univ TCM, Inst Surg, Sch Med & Life Sci, Chengdu 610075, Peoples R China; [Guo, Haiyang; Zhang, Jun; Qin, Chao; Yan, Hang; Luo, Xinyue; Zhou, Haining] Chongqing Med Univ, Suining Cent Hosp, Affiliated Hosp, Suining, Peoples R China; [Zhang, Jun; Qin, Chao; Yan, Hang; Zhou, Haining] Zunyi Med Univ, Inst Surg, Grad Sch, Zunyi, Peoples R China"

通信作者："Zhou, HN (通讯作者)，Chengdu Univ TCM, Inst Surg, Sch Med & Life Sci, Chengdu 610075, Peoples R China."

来源：MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001145855300019

JCR分区：Q2

影响因子：1.6

年份：2024

卷号：103

期号：3

开始页：　

结束页：　

文献类型：Article

关键词：biomarkers; chemotherapy; CTLA-4; immune checkpoint inhibitors; NSCLC; PD-1; PD-L1

摘要："The current use of immune checkpoint inhibitors (ICIs) for the treatment of lung cancer has dramatically changed the clinical strategy for metastatic non-small cell lung cancer (mNSCLC). As a result of great achievements in clinical trials, 6 programmed death-1 inhibitors (sintilimab, camrelizumab, tislelizumab, pembrolizumab, cemiplimab, and nivolumab), 2 programmed death-ligand 1 inhibitors (sugemalimab and atezolizumab), and 1 cytotoxic T lymphocyte-associated antigen-4 inhibitor (ipilimumab) have been approved as first-line treatment for mNSCLC by the US Food and Drug Administration. Recently, research on ICIs has shifted from a large number of second-line to first-line settings in clinical trials. Results from first-line trials have shown that almost all driver-negative mNSCLC are treated with ICIs and significantly prolong patient survival; however, the low response rate and adverse reactions to immunotherapy remain to be addressed. Here, we summarize the use of ICIs, including monotherapy and combination therapy, in the first-line treatment of mNSCLC in recent years and discuss the low response rate and adverse reactions of ICIs as well as the challenges and expectations for the first-line treatment of mNSCLC in the future."

基金机构：Chengdu University of Traditional Chinese Medicine [YYZX2020093]; Health Department of Sichuan Province [21PJ188]

基金资助正文："This research was funded by Chengdu University of Traditional Chinese Medicine, grant number YYZX2020093 and Health Department of Sichuan Province, grant number 21PJ188."